Healthcare
Kura Oncology, Inc.(KURA)
Live Price
Offline$9.05
+2.14% today
1Y Change
+65.00%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $780.00M
- Revenue Growth
- +25.2%
- EPS Growth
- -57.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kura Oncology, Inc. (KURA) is a Healthcare stock with a market cap of $780.00M and listed on NASDAQ. The stock last traded around $9.05 and up 65.0% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +25.2%, EPS growth of -57.4%, a dividend yield of 0.0%. What stands out right now is revenue +25.2%, EPS -57.4%, free cash flow -152.8% with operating margin -449.9% and ROIC -48.8%. Valuation already assumes a fairly strong business story at price/sales 11.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KURA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+25.2% vs +7.6% peer median
Operating Margin
Below sector median
-449.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +25.2% and EPS is at -57.4%, with operating margin around -449.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +1.1% | +4.5% | -6.2% |
2026 Mar 5, 2026 | -27.8% | +5.3% | +3.9% | +1.2% |
2025 Nov 4, 2025 | -49.1% | -0.2% | +7.3% | +20.2% |
Benchmark Edge
KURA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KURA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KURA Max Drawdown
-39.04%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KURA and SPY.
Company Overview
Kura Oncology, Inc.
NASDAQ Global Select
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
- Leadership
- Troy Edward Wilson
- IPO Date
- Sep 16, 2015
- Employees
- 192
- Street Address
- 12730 High Bluff Drive
- Mailing
- San Diego, CA, 92130
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 500 8800
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 11.5
- Price/Book
- 4.4
Growth
- Revenue
- +25.2%
- EPS
- -57.4%
- Free Cash Flow
- -152.8%
Profitability
- Gross Margin
- 94.6%
- Operating Margin
- -449.9%
- Net Margin
- -412.9%
- ROE
- -102.6%
- ROIC
- -48.8%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 6.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.